A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells

Chi Chen Lin, Yen Ling Yu, Chia Chiao Shih, Ko Jiunn Liu, Keng Liang Ou, Ling Zong Hong, Jody D.C. Chen, Ching Liang Chu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

DNA vaccine has been suggested to use in cancer therapy, but the efficacy remains to be improved. The immunostimulatory effect of a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) isolated from Ganoderma lucidum has been reported. In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185neu expressing tumor MBT-2 in mice. We found that recombinant LZ-8 stimulated mouse bone marrow-derived dendritic cells (DCs) via TLR4 and its stimulatory effect was not due to any microbe contaminant. In addition, LZ-8 enhanced the ability of DCs to induce antigen-specific T cell activation in vitro and in a subunit vaccine model in vivo. Surprisingly, LZ-8 cotreatment strongly improved the therapeutic effect of DNA vaccine against MBT-2 tumor in mice. This increase in antitumor activity was attributed to the enhancement of vaccine-induced Th1 and CTL responses. Consistent with the results from DCs, the promoting effect of LZ-8 on DNA vaccine was diminished when the MBT-2 tumor cells were grown in TLR4 mutant mice. Thus, we concluded that LZ-8 may be a promising adjuvant to enhance the efficacy of DNA vaccine by activating DCs via TLR4.

Original languageEnglish
Pages (from-to)1019-1027
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume60
Issue number7
DOIs
Publication statusPublished - 2011

Fingerprint

Cancer Vaccines
DNA Vaccines
Dendritic Cells
Neoplasms
CD27 Antigens
Reishi
Subunit Vaccines
Fungal Proteins
Therapeutic Uses
Vaccines
Bone Marrow

Keywords

  • Adjuvant
  • Cancer therapy
  • Dendritic cell
  • DNA vaccine
  • TLR4

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Lin, C. C., Yu, Y. L., Shih, C. C., Liu, K. J., Ou, K. L., Hong, L. Z., ... Chu, C. L. (2011). A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunology, Immunotherapy, 60(7), 1019-1027. https://doi.org/10.1007/s00262-011-1016-4

A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. / Lin, Chi Chen; Yu, Yen Ling; Shih, Chia Chiao; Liu, Ko Jiunn; Ou, Keng Liang; Hong, Ling Zong; Chen, Jody D.C.; Chu, Ching Liang.

In: Cancer Immunology, Immunotherapy, Vol. 60, No. 7, 2011, p. 1019-1027.

Research output: Contribution to journalArticle

Lin, CC, Yu, YL, Shih, CC, Liu, KJ, Ou, KL, Hong, LZ, Chen, JDC & Chu, CL 2011, 'A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells', Cancer Immunology, Immunotherapy, vol. 60, no. 7, pp. 1019-1027. https://doi.org/10.1007/s00262-011-1016-4
Lin, Chi Chen ; Yu, Yen Ling ; Shih, Chia Chiao ; Liu, Ko Jiunn ; Ou, Keng Liang ; Hong, Ling Zong ; Chen, Jody D.C. ; Chu, Ching Liang. / A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. In: Cancer Immunology, Immunotherapy. 2011 ; Vol. 60, No. 7. pp. 1019-1027.
@article{eaf65f72ca8b4c18b5c75ee9b67bbc19,
title = "A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells",
abstract = "DNA vaccine has been suggested to use in cancer therapy, but the efficacy remains to be improved. The immunostimulatory effect of a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) isolated from Ganoderma lucidum has been reported. In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185neu expressing tumor MBT-2 in mice. We found that recombinant LZ-8 stimulated mouse bone marrow-derived dendritic cells (DCs) via TLR4 and its stimulatory effect was not due to any microbe contaminant. In addition, LZ-8 enhanced the ability of DCs to induce antigen-specific T cell activation in vitro and in a subunit vaccine model in vivo. Surprisingly, LZ-8 cotreatment strongly improved the therapeutic effect of DNA vaccine against MBT-2 tumor in mice. This increase in antitumor activity was attributed to the enhancement of vaccine-induced Th1 and CTL responses. Consistent with the results from DCs, the promoting effect of LZ-8 on DNA vaccine was diminished when the MBT-2 tumor cells were grown in TLR4 mutant mice. Thus, we concluded that LZ-8 may be a promising adjuvant to enhance the efficacy of DNA vaccine by activating DCs via TLR4.",
keywords = "Adjuvant, Cancer therapy, Dendritic cell, DNA vaccine, TLR4",
author = "Lin, {Chi Chen} and Yu, {Yen Ling} and Shih, {Chia Chiao} and Liu, {Ko Jiunn} and Ou, {Keng Liang} and Hong, {Ling Zong} and Chen, {Jody D.C.} and Chu, {Ching Liang}",
year = "2011",
doi = "10.1007/s00262-011-1016-4",
language = "English",
volume = "60",
pages = "1019--1027",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",

}

TY - JOUR

T1 - A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells

AU - Lin, Chi Chen

AU - Yu, Yen Ling

AU - Shih, Chia Chiao

AU - Liu, Ko Jiunn

AU - Ou, Keng Liang

AU - Hong, Ling Zong

AU - Chen, Jody D.C.

AU - Chu, Ching Liang

PY - 2011

Y1 - 2011

N2 - DNA vaccine has been suggested to use in cancer therapy, but the efficacy remains to be improved. The immunostimulatory effect of a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) isolated from Ganoderma lucidum has been reported. In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185neu expressing tumor MBT-2 in mice. We found that recombinant LZ-8 stimulated mouse bone marrow-derived dendritic cells (DCs) via TLR4 and its stimulatory effect was not due to any microbe contaminant. In addition, LZ-8 enhanced the ability of DCs to induce antigen-specific T cell activation in vitro and in a subunit vaccine model in vivo. Surprisingly, LZ-8 cotreatment strongly improved the therapeutic effect of DNA vaccine against MBT-2 tumor in mice. This increase in antitumor activity was attributed to the enhancement of vaccine-induced Th1 and CTL responses. Consistent with the results from DCs, the promoting effect of LZ-8 on DNA vaccine was diminished when the MBT-2 tumor cells were grown in TLR4 mutant mice. Thus, we concluded that LZ-8 may be a promising adjuvant to enhance the efficacy of DNA vaccine by activating DCs via TLR4.

AB - DNA vaccine has been suggested to use in cancer therapy, but the efficacy remains to be improved. The immunostimulatory effect of a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) isolated from Ganoderma lucidum has been reported. In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185neu expressing tumor MBT-2 in mice. We found that recombinant LZ-8 stimulated mouse bone marrow-derived dendritic cells (DCs) via TLR4 and its stimulatory effect was not due to any microbe contaminant. In addition, LZ-8 enhanced the ability of DCs to induce antigen-specific T cell activation in vitro and in a subunit vaccine model in vivo. Surprisingly, LZ-8 cotreatment strongly improved the therapeutic effect of DNA vaccine against MBT-2 tumor in mice. This increase in antitumor activity was attributed to the enhancement of vaccine-induced Th1 and CTL responses. Consistent with the results from DCs, the promoting effect of LZ-8 on DNA vaccine was diminished when the MBT-2 tumor cells were grown in TLR4 mutant mice. Thus, we concluded that LZ-8 may be a promising adjuvant to enhance the efficacy of DNA vaccine by activating DCs via TLR4.

KW - Adjuvant

KW - Cancer therapy

KW - Dendritic cell

KW - DNA vaccine

KW - TLR4

UR - http://www.scopus.com/inward/record.url?scp=85027957698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027957698&partnerID=8YFLogxK

U2 - 10.1007/s00262-011-1016-4

DO - 10.1007/s00262-011-1016-4

M3 - Article

AN - SCOPUS:85027957698

VL - 60

SP - 1019

EP - 1027

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 7

ER -